Will Botox's market share remain strong if rivals launch anti-wrinkle injections?

Jan 10 (Reuters) - AbbVie expects Botox's market share in the aesthetics space to remain strong even as rivals launch competing anti-wrinkle injections, a company executive said on Wednesday. Botox sales, especially for aesthetic use, have been under pressure over the last few quarters due to economic uncertainties.

Does AbbVie have a market share in Botox?

Shares of AbbVie were up nearly 1% in afternoon trade. (Reporting by Leroy Leo and Pratik Jain in Bengaluru; Editing by Pooja Desai and Devika Syamnath) AbbVie expects Botox's market share in the aesthetics space to remain strong even as rivals launch competing anti-wrinkle injections, a company executive said on Wednesday.

Why are Botox sales under pressure?

Botox sales, especially for aesthetic use, have been under pressure over the last few quarters due to economic uncertainties. Investors have also been concerned about potential market share losses to new entrants such as Revance Therapeutics' Daxxify and Evolus' Jeuveau.